<unk> , sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.<unk>  was approved for medical use in the United States in November 2015, and in the European Union in February 2016.
Osimertinib
Mobocertinib
Lestaurtinib
Upadacitinib
Abrocitinib
Axitinib
Selpercatinib
Icotinib